Latest Tax News

Kimberly-Clark has completed its acquisition of Kenvue, issuing about 281.1 million shares and taking on an integration programme expected to cost US$3.1 billion before tax. The combined group is targeting US$2.1 billion in annual run-rate synergies by reshaping its brands, segments and operating model.

PSEG increased third-quarter non-GAAP operating earnings and reaffirmed its full-year outlook, even as GAAP net income fell sharply on market-related effects. The New Jersey utility is also advancing a US$24 billion to US$28 billion five-year investment programme without planned new equity issuance.

Lumentum delivered a 136.5% year-on-year revenue surge in fiscal Q1 2027 and forecast a further step-up to as much as US$1.625 billion in the next quarter. Management also disclosed purchase commitments exceeding US$5 billion linked to a second major NPO/CPO win, though the timing and enforceability of those commitments were not detailed.

IDEXX Laboratories has raised its 2026 revenue and earnings outlook after reporting 10% third-quarter revenue growth and an 18% rise in diluted EPS. The upgrade came alongside rapid adoption of its inVue Dx analyzers, although acquisition costs prompted a lower full-year operating margin forecast.

Loews Corporation (NYSE:L) reported third-quarter net income of US$306 million, down 39% from a year earlier, after CNA’s long-term care reserve review cut attributable earnings by US$125 million. Stronger hotel performance and share buybacks offered some support, but CNA’s underwriting trends remain a central concern.

Global Masters Fund will pay its first-ever dividend, a 15.0 cent per share special distribution that is fully franked and sourced from taxable capital gains. The payment marks a deliberate transition for the listed investment company, not the start of a regular dividend stream.

Noxopharm has secured a $1.5 million placement and agreed to convert $3.78 million of shareholder notes as it prepares to test SOF-SKN in cutaneous lupus patients. The funding eases an immediate cash constraint, but the package also brings substantial dilution and remains partly subject to shareholder approval.

Lithium Plus Minerals has secured A$1.6575 million at A$0.10 a share, with cornerstone backing from Suzhou CATH Energy Technologies and a further A$1 million SPP planned. The funding is aimed at moving the Lei direct shipping ore project into pre-feasibility while supporting resource growth and offtake discussions.

Orezone Gold has put a US$1.05 billion after-tax valuation on a 14-year Casa Berardi mine plan, with a planned East Mine restart and 1.63 million ounces of production. The economic case remains preliminary, includes Inferred Resources and reports no Mineral Reserves.

Neurizon Therapeutics has secured A$4.3 million through a discounted placement and is seeking another A$2.0 million from eligible shareholders, while redeeming its remaining Obsidian convertible notes. The move removes current note-conversion dilution, but shifts funding risk towards equity holders ahead of a pivotal NUZ-001 trial readout.

Proteomics International has launched a discounted A$5 million share purchase plan as it moves from product development into commercial rollout. Eligible shareholders can buy shares at A$0.10 and may receive a free attaching option, subject to approval.

Euroz Hartleys has completed the sale of its Capital Markets business to BMO Financial Group for A$145 million, subject to completion adjustments. The ASX-listed company will now focus on private wealth and expects to return the post-tax proceeds to shareholders through a fully franked special dividend and an equal return of capital.